Pharmacokinetics of Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Tuberculosis
Status:
Unknown status
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
In this pilot study the pharmacokinetics and safety of the antiretroviral combination of
co-formulated emtricitabine/tenofovir/efavirenz will be studied in HIV-positive patients with
pulmonary tuberculosis (TB) who are concomitantly treated with a standard rifampin-containing
tuberculostatic regimen. It is expected that this antiretroviral combination causes minimal
drug interactions with the rifampin-containing anti-tuberculosis medication.
Phase:
Phase 2
Details
Lead Sponsor:
African Poverty Related Infection Oriented Research Initiative
Collaborators:
Kilimanjaro Christian Medical Centre, Tanzania Radboud University
Treatments:
Efavirenz Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir